Characterization of IMP-1, a major carbapenem resistance factor in bacteria

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H04868
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Infectious disease medicine
• Research Institution: Nagoya University
• Principal Investigator: Arakawa Yoshichika 名古屋大学, 医学系研究科, 教授 (10212622)
• Co-Investigator(Renkei-kenkyūsha): KIMURA Kouji 名古屋大学, 大学院医学系研究科, 准教授 (50425675) ; WACHINO Jun-ichi 名古屋大学, 大学院医学系研究科, 講師 (00535651)
• Research Collaborator: JIN Wanchun 名古屋大学, 大学院医学系研究科, 特任助教 ; ANUPRIYA Kumar 名古屋大学, 大学院医学系研究科, 特任助教 ; BANNO Hirotsugu 名古屋大学, 大学院医学系研究科 ; KITAOKA Kazuki 名古屋大学, 大学院医学系研究科 ; KANECHI Leo 名古屋大学, 大学院医学系研究科 ; KANAYAMA Takato 名古屋大学, 大学院医学系研究科
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 薬剤耐性菌

Outline of Final Research Achievements

Emerging of drug-resistant bacteria is a major clinical concern. Thus, it is essential to develop new antibiotics and agents to overcome the problem of drug-resistant bacteria. To respond to the aforementioned urgent and unmet needs, we have screened for metallo-beta-lactamase (MBL) inhibitor. MBL inhibitor can revive the efficacy of carbapenem antibiotics. We have screened 2107 small molecule compounds to identify IMP-1 inhibitor, IMP-1 is the dominant MBL in clinically isolated Enterobacteriaceae. Enzymatic and biological analyses revealed that 8 compounds would be candidates of IMP-1 inhibitor. These 8 compounds would be a great help to overcome carbapenem resistance caused by production of IMP-type MBL.

Free Research Field

細菌学